Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment

J Am Acad Dermatol. 2016 Jan;74(1):177-9. doi: 10.1016/j.jaad.2015.08.010.

Authors

Juul M P A van den Reek¹, Philippe A R R Pijls², Marcia Tummers³, Piet C L M van Riel⁴, Wietske Kievit³, Frank Hoentjen², Elke M G J de Jong⁵

Affiliations

¹ Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Juul.vandenReek@Radboudumc.nl.
² Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
⁴ Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
⁵ Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 26702800
DOI: 10.1016/j.jaad.2015.08.010

No abstract available

Publication types

Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / mortality
Confidence Intervals
Crohn Disease / diagnosis
Crohn Disease / drug therapy*
Crohn Disease / mortality
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Male
Proportional Hazards Models
Psoriasis / diagnosis
Psoriasis / drug therapy*
Psoriasis / mortality
Registries
Retrospective Studies
Survival Rate
Time Factors

Substances

Antibodies, Monoclonal, Humanized
Adalimumab